Scarica l'app Stockscreener
59.82
1.53%
0.90
Dopo l'orario di chiusura:
59.82
Precedente Chiudi:
$58.92
Aprire:
$59
Volume 24 ore:
596.37K
Relative Volume:
0.43
Capitalizzazione di mercato:
$4.38B
Reddito:
-
Utile/perdita netta:
$-98.78M
Rapporto P/E:
-35.95
EPS:
-1.6638
Flusso di cassa netto:
$-65.60M
1 W Prestazione:
+1.70%
1M Prestazione:
+10.10%
6M Prestazione:
+129.90%
1 anno Prestazione:
+201.51%
Intervallo 1D:
$58.83
$60.00
Intervallo di 1 settimana:
$57.07
$61.21
Portata 52W:
$14.79
$62.32
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Nome
Enliven Therapeutics Inc
Settore
Industria
Telefono
720-647-8519
Indirizzo
6200 LOOKOUT ROAD, BOULDER
Compare ELVN vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
59.82 | 4.32B | 0 | -98.78M | -65.60M | -1.6638 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-16 | Iniziato | Goldman | Buy |
| 2024-12-13 | Iniziato | BTIG Research | Buy |
| 2024-09-09 | Iniziato | H.C. Wainwright | Buy |
| 2024-06-11 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-09 | Iniziato | Mizuho | Buy |
| 2023-03-29 | Iniziato | Jefferies | Buy |
Mostra tutto
Enliven Therapeutics Inc Borsa (ELVN) Ultime notizie
Enliven (ELVN) Earnings Snapshot: EPS Falls Short of Its Estimate in the Reported Period; Share Response: The Stock Records a 0.79% Decrease on the DayProfit Cycle Analysis - vinanet.vn
ELVN Stock On Track For Best Week Since March Following FDA-Aligned Path For Cancer Drug Development - Stocktwits
Handelsbanken Fonder AB Buys New Shares in Enliven Therapeutics, Inc. $ELVN - MarketBeat
Enliven Therapeutics CFO Benjamin Hohl Executes Two Stock Sales on August 17 Under 10b5-1 Plan - Kalkine Media
Benjamin Hohl Sells 6,018 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock - MarketBeat
Enliven (NASDAQ: ELVN) CFO sells 6,018 shares in 10b5-1 plan - Stock Titan
Enliven Therapeutics (ELVN) CMO exercises options, sells stock - Stock Titan
Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says - Sahm
Barclays Initiates Enliven Therapeutics at Overweight With $78 Price Target - Moomoo
What's Going On With Enliven Therapeutics Stock Tuesday?Enliven Therapeutics (NASDAQ:ELVN) - Benzinga
Enliven a new outperform at Barclays on potential of CML asset - Seeking Alpha
Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Analysts at William Blair - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Barclays - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Given New $73.00 Price Target at Mizuho - MarketBeat
Barclays initiates Enliven Therapeutics stock at Overweight, $78 PT By Investing.com - Investing.com Canada
William Blair Initiates Enliven Therapeutics at Outperform - marketscreener.com
William Blair initiates Enliven Therapeutics stock with outperform rating By Investing.com - Investing.com Canada
261,344 Shares in Enliven Therapeutics, Inc. $ELVN Acquired by TimesSquare Capital Management LLC - MarketBeat
ENLIVEN THERAPEUTICS, INC. : WILLIAM BLAIR INITIATES COVERAGE WITH OUTPERFORM RATING - Bitget
symbol__ Stock Quote Price and Forecast - CNN
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $82 - Moomoo
Tema ETFs LLC Grows Stake in Enliven Therapeutics, Inc. $ELVN - MarketBeat
FMR LLC Boosts Stake in Enliven Therapeutics Inc (ELVN) with Str - GuruFocus
Janus Henderson Group PLC Sells 1,660,724 Shares of Enliven Therapeutics, Inc. $ELVN - MarketBeat
Assenagon Asset Management S.A. Makes New Investment in Enliven Therapeutics, Inc. $ELVN - MarketBeat
Enliven Therapeutics (ELVN) Pulls Back 1.44% to $58.56 as Support HoldsInsider Sentiment - vinanet.vn
Certain Options of Enliven Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-AUG-2026. - marketscreener.com
Certain Common Stock of Enliven Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-AUG-2026. - marketscreener.com
How (ELVN) Movements Inform Risk Allocation Models - Stock Traders Daily
LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $70 - Moomoo
Enliven Therapeutics (NASDAQ:ELVN) Stock Rating Lowered by Wall Street Zen - MarketBeat
LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $70 - Moomoo
Enliven Therapeutics director Mika Derynck sells $9.56m shares By Investing.com - Investing.com South Africa
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Enliven Therapeutics (ELVN) and Geron (GERN) - The Globe and Mail
We're Interested To See How Enliven Therapeutics (NASDAQ:ELVN) Uses Its Cash Hoard To Grow - Moomoo
Enliven Therapeutics director Mika Derynck sells $9.56m shares - Investing.com
Enliven Therapeutics (ELVN) director exercises options, sells 158,795 shares - Stock Titan
Enliven Therapeutics (NASDAQ:ELVN) Director Sells 158,795 Shares of Stock - MarketBeat
Insider Sale: Director at $ELVN Sells 158,795 Shares - Moomoo
A Quick Look at Today's Ratings for Enliven Therapeutics(ELVN.US), With a Forecast Between $68 to $82 - Moomoo
Enliven Therapeutics, Inc. Stock 12‑Month Price Target Raised to $70.9, Implies 19% Upside - TradingView
Enliven Therapeutics director Mika K. Derynck sells USD 9.56 million in common shares - Bitget
Stifel Nicolaus Issues Positive Forecast for Enliven Therapeutics (NASDAQ:ELVN) Stock Price - marketbeat.com
FMR LLC and Abigail Johnson disclose 15% Enliven Therapeutics (ELVN) ownership - stocktitan.net
Guggenheim lowers Enliven Therapeutics stock price target to $78 By Investing.com - Investing.com Canada
Dimensional Fund Advisors LP Raises Holdings in Enliven Therapeutics, Inc. $ELVN - MarketBeat
ENLIVEN THERAPEUTICS, INC. : JEFFERIES RAISES TARGET PRICE TO $69 FROM $59 - Bitget
Enliven Therapeutics, Inc. 2Q 2026: Net loss $32.5M, EPS $(0.49) — 10-Q Summary - TradingView
ELVN: Strong Phase 1 results and FDA alignment set up ENABLE-2 trial, with $895M cash runway into 2030 - TradingView
ELVN: Net loss widened on higher R&D costs; strong cash reserves support pivotal ELVN-001 trial - TradingView
Enliven Therapeutics Inc Azioni (ELVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.21%
1.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):